Establishment Labs Holdings Inc
Establishment Labs Holdings Inc. develops and commercializes aesthetic and reconstructive breast implant products, centered on its Motiva Implants platform and related minimally invasive offerings. The company also manufactures its own products in Costa Rica and sells through distributors as well as direct relationships with physicians, hospitals, and clinics.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSilicone breast implants sold for aesthetic augmentation and reconstruction.
Temporary implantable devices used to prepare tissue for reconstruction.
Products and procedures such as Preservé and Mia Femtech that broaden the portfolio beyond standard implants.
RFID-based transponders and related technology used to support product identification and safety.
Customers
The company sells primarily to medical distributors and directly to physicians, hospitals, and clinics that implant or stock its products. End demand is driven by plastic surgeons and other aesthetic or reconstructive providers serving patients seeking breast augmentation, revision, or reconstruction. Adoption depends on clinical differentiation, regulatory approvals, and physician confidence in safety and outcomes data.
Buy inventory for resale in approved markets and help the company reach fragmented international channels.
Purchase directly or use consigned inventory for breast augmentation and reconstruction procedures.
Stock products for surgical use, especially where consignment arrangements support procedure-based demand.
Adopt Motiva products to differentiate offerings and improve patient conversion and satisfaction.
Strategy
Management is focused on expanding U.S. sales, growing in existing international markets, and broadening the portfolio with minimally invasive products. The company is also using marketing, education, and selective acquisitions to improve patient conversion and strengthen its competitive position against larger implant makers.
The U.S. is a large market and Motiva is newly approved there, creating a major growth runway.
The company already sells in many countries and can leverage existing approvals and distributor relationships.
Minimally invasive products can widen the addressable market and reduce reliance on standard implants.
Physician education and patient awareness are critical in a preference-driven aesthetic market.
Geography
Q1/2026The company sells in more than 100 countries and only began commercial U.S. sales in late 2024 after FDA approval of Motiva Implants. Manufacturing is concentrated in Costa Rica, where two ISO-13485-certified facilities support global supply and where the company also benefits from a tax holiday. Geography matters because revenue is exposed to foreign exchange, regulatory approvals, and market-by-market pricing pressure.
Share of the revenue the company reports by geography.
Risks
The business faces regulatory, competitive, and commercialization risk because it depends on approvals, physician adoption, and continued market access across many jurisdictions. It also has meaningful financing and execution risk as a growth-stage medical device company with ongoing operating cash use and a need to scale manufacturing, sales, and working capital.
- Regulatory approval delays or denialsImpact: HighLikelihood: Medium
The company needs approvals to commercialize new products and expand into new markets.
Exposure: New products and geographic expansion
- Competitive pressure from larger implant makersImpact: HighLikelihood: Medium
Competitors have greater resources, broader relationships, and established distribution networks.
Exposure: Breast implant market
- Need for additional capitalImpact: HighLikelihood: Medium
Growth, commercialization, and manufacturing expansion may require external financing.
Exposure: Liquidity and dilution risk
- Pricing pressure in a price-sensitive marketImpact: MediumLikelihood: Medium
Aggressive discounting by competitors can force lower prices or reduce conversion rates.
Exposure: United States and international implant markets
- Limited U.S. operating historyImpact: MediumLikelihood: Medium
The company has only recently begun U.S. commercial sales, so demand and execution are less proven.
Exposure: U.S. market entry
Accounting
Judgemental itemsRevenue is deferred until implantation, affecting quarter-to-quarter comparability.
Impact: Can shift revenue between periods and affect reported growth
The company sells globally and reports in U.S. dollars while incurring costs in multiple currencies.
Impact: Can materially affect revenue, gross margin, and operating results
New Costa Rica facilities increase fixed assets and depreciation while ramping utilization.
Impact: Can pressure gross margin during expansion phases
A 0% tax rate under a local tax holiday can materially affect effective tax expense.
Impact: Can make tax expense unusually low versus normalized levels
Similar listed companies
Publicly listed companies with a comparable business focus.
Fortrea Holdings Inc.
FTRE · Services-Medical Laboratories
Integra LifeSciences Holdings Corporation
IART · Surgical & Medical Instruments & Apparatus
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
Family Office Of America, Inc.
FOFA · Surgical & Medical Instruments & Apparatus
Envista Holdings Corp
NVST · Dental Equipment & Supplies
Envista Holdings Corp is a U.S.-based dental products company built around more than 30 brands, including Nobel Biocare, Ormco, DEXIS, and Kerr.
Monte Rosa Therapeutics, Inc.
GLUE · Biological Products, (No Diagnostic Substances)
Monte Rosa Therapeutics is a biotechnology company developing small-molecule molecular glue degraders (MGDs) that use the cell’s own protein-destruction…
Last updated: 24/09/2026